ABBV vs TSLA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Tesla, Inc. · Consumer Cyclical
$400.49
-1.1% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
ABBV trades at a lower forward P/E
(128.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
TSLA |
| Current Price |
$261.07 |
$400.49 |
| Fair Value Estimate |
$264.30 |
$396.15 |
| Upside to Fair Value |
+1.2%
|
-1.1%
|
| Market Cap |
$461.3B |
$1,504.1B |
| Forward P/E |
128.0x
|
334.1x
|
| EV / EBITDA |
31.0x
|
124.0x
|
| Price / Sales |
7.3x
|
15.4x
|
| Price / FCF |
22.1x
|
214.9x
|
| Revenue Growth YoY |
+12.4%
|
+15.8%
|
| Gross Margin |
70.7%
|
19.1%
|
| Operating Margin |
27.6%
|
5.0%
|
| Return on Equity |
68.0%
|
4.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
0.47%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Tesla, Inc. is a leading global electric vehicle manufacturer and energy solutions provider, led by CEO Elon Musk since 2008. The company maintains a strong position in the EV market with a unique fast-charging and software ecosystem, although its EV market share is declining amid intensifying competition. Tesla's business quality is medium due to its narrowing moat and modest profitability, with…
Accumulation Zones
| Metric |
ABBV |
TSLA |
| Zone Low |
$198.23 |
$297.11 |
| Zone High |
$224.66 |
$336.73 |
| In Buy Zone? |
No
|
No
|